febuxostat has been researched along with Left Ventricular Hypertrophy in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, J; Lin, H; Pan, JA; Wang, CQ; Zhang, JF | 1 |
| Ito, O; Kohzuki, M; Kurosawa, R; Miura, T; Nakamura, T; Namai-Takahashi, A; Sakuyama, A; Takahashi, J | 1 |
| Butt, NF; Iqbal, A; Lal, B; Randhawa, FA; Rathore, R; Waseem, T | 1 |
| Bache, RJ; Chen, Y; Hu, X; Lu, Z; Wessale, JL; Xu, X; Zhang, P; Zhao, L | 1 |
| Bache, R; Chen, Y; Hu, X; Wessale, J; Xu, X; Zhang, P; Zhao, L | 1 |
| Schmidt, BM; Wagner, AD | 1 |
1 review(s) available for febuxostat and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
[Hyperuricemia, gout, pseudogout and concomitant diseases].
Topics: Allopurinol; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Chondrocalcinosis; Comorbidity; Diabetes Mellitus, Type 2; Febuxostat; Gout; Gout Suppressants; Guideline Adherence; Humans; Hypertrophy, Left Ventricular; Hyperuricemia; Interleukin 1 Receptor Antagonist Protein; Kidney Failure, Chronic; Thiazoles; Xanthine Oxidase | 2011 |
1 trial(s) available for febuxostat and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Efficacy of high dose Allopurinol in reducing left ventricular mass in patients with left ventricular hypertrophy by comparing its efficacy with Febuxostat - a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Allopurinol; Antimetabolites; Blood Pressure; Dose-Response Relationship, Drug; Echocardiography; Febuxostat; Female; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Male; Middle Aged; Treatment Outcome; Ventricular Function, Left; Young Adult | 2018 |
4 other study(ies) available for febuxostat and Left Ventricular Hypertrophy
| Article | Year |
|---|---|
Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.
Topics: Aged; Asymptomatic Diseases; Biomarkers; Blood Pressure; Databases, Factual; Diastole; Disease Progression; Drug Prescriptions; Febuxostat; Female; Gout Suppressants; Heart Disease Risk Factors; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Hyperuricemia; Male; Middle Aged; Protective Factors; Retrospective Studies; Risk Assessment; Stroke Volume; Time Factors; Uric Acid; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2020 |
Xanthine Oxidase Inhibitor, Febuxostat Ameliorates the High Salt Intake-Induced Cardiac Hypertrophy and Fibrosis in Dahl Salt-Sensitive Rats.
Topics: Animals; Collagen; Disease Models, Animal; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Febuxostat; Fibrosis; Heart Ventricles; Hypertrophy, Left Ventricular; Male; NADPH Oxidases; Phosphorylation; Rats, Inbred Dahl; Reactive Oxygen Species; Renin-Angiotensin System; Sodium Chloride, Dietary; Transforming Growth Factor beta1; Ventricular Function, Left; Ventricular Remodeling; Xanthine Oxidase | 2019 |
Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice.
Topics: Animals; Disease Models, Animal; Febuxostat; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Systole; Thiazoles; Ventricular Dysfunction, Left | 2008 |
Delayed treatment effects of xanthine oxidase inhibition on systolic overload-induced left ventricular hypertrophy and dysfunction.
Topics: Allopurinol; Animals; Constriction, Pathologic; Enzyme Inhibitors; Febuxostat; Hypertrophy, Left Ventricular; Male; Mice; Mice, Inbred C57BL; Thiazoles; Xanthine Oxidase | 2010 |